E
Arvinas, Inc. ARVN
$9.93 -$0.01-0.05% NASDAQ
Recommendation
Prev Close
$9.93
Volume
849,470
Avg Vol (90D)
2,077,817
Market Cap
$729.04M
Dividend & Yield
--
52-Week Range
$5.90 - $28.83
P/E (TTM)
--
EPS (TTM)
-$1.01
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Financial Analysis: Arvinas (NASDAQ:ARVN) versus Pharming Group (OTCMKTS:PHGUF)
10/31/2025 - Ticker Report
ARVN Crosses Above Key Moving Average Level
10/30/2025 - Market News Video
BTIG Maintains Buy Rating on Arvinas (ARVN), Raises Price Target to $14.00 ARVN Stock News
10/30/2025 - GuruFocus
Arvinas price target raised by $4 at BTIG, here's why
10/30/2025 - The Fly
Arvinas to Report Third Quarter 2025 Financial Results on November 5, 2025
10/29/2025 - GuruFocus
Arvinas to Report Third Quarter 2025 Financial Results on November 5, 2025
10/29/2025 - Globe Newswire
Arvinas (ARVN, $9.5) entered Uptrend as Momentum indicator ascends above 0 level on Oct 28, 2025
10/29/2025 - Tickeron - Stocks
Analysts Set Arvinas, Inc. (NASDAQ:ARVN) Price Target at $16.18
10/28/2025 - Ticker Report
Arvinas Advances in KRAS G12D Mutation Treatment with ARV-806 Study
10/27/2025 - TipRanks Financial Blog
Arvinas' ARV-393: A New Hope in Non-Hodgkin's Lymphoma Treatment?
10/27/2025 - TipRanks Financial Blog
The Math Shows BMED Can Go To $32
10/27/2025 - ETF Channel
Allspring Global Investments Holdings LLC Has $327,000 Stock Position in Arvinas, Inc. $ARVN
10/26/2025 - MarketBeat
Weiss Ratings Reiterates Sell (E+) Rating for Arvinas (NASDAQ:ARVN)
10/25/2025 - MarketBeat
Arvinas (ARVN) Unveils Promising Preclinical Data for KRAS G12D Degrader ARV-806
10/24/2025 - GuruFocus
Arvinas presents preclinical data for ARV-806
10/24/2025 - TipRanks Financial Blog
Arvinas presents preclinical data for ARV-806
10/24/2025 - The Fly
Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
10/24/2025 - Globe Newswire
TD Asset Management Inc Lowers Stock Holdings in Arvinas, Inc. $ARVN
10/24/2025 - MarketBeat
Arvinas (ARVN, $9.16) price may climb as it broke lower Bollinger Band on Oct 23, 2025
10/24/2025 - Tickeron - Stocks
Alnylam Pharmaceuticals (ALNY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
10/23/2025 - Zacks Investment Research
FNY Investment Advisers LLC Purchases Shares of 37,520 Arvinas, Inc. $ARVN
10/23/2025 - MarketBeat
Arvinas (ARVN, $9.31) entered Downtrend as Momentum indicator drops below 0 level on Oct 22, 2025
10/23/2025 - Tickeron - Stocks
Arvinas, Inc. (NASDAQ:ARVN) Receives Average Recommendation of "Hold" from Analysts
10/23/2025 - MarketBeat
Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 ...
10/22/2025 - GuruFocus
Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
10/22/2025 - Globe Newswire
Income Statement
Total Revenue (TTM)
$372.80M
EBITDA (TTM)
-$113.90M
EBIT (TTM)
-$117.60M
Net Income (TTM)
-$72.60M
Balance Sheet
Total Assets (Q)
$909.30M
Total Debt (Q)
$9.90M
Total Liabilities (Q)
$300.00M
Book Value Per Share (Q)
$8.32
Cash Flow
Cash from Operations (TTM)
-$396.40M
Cash from Investing (TTM)
$347.70M
Cash from Financing (TTM)
$3.30M
Net Change in Cash (TTM)
-$45.40M
Filings
Filing Date
Wednesday, August 6, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Oct 27 and 31 (est)
Price History
Loading...
Beta
2.36
7-Day Total Return
6.61%
30-Day Total Return
31.98%
60-Day Total Return
59.05%
90-Day Total Return
27.24%
Year to Date Total Return
-47.46%
1-Year Total Return
-62.45%
2-Year Total Return
-38.43%
3-Year Total Return
-80.03%
5-Year Total Return
-54.62%
52-week Low
May 15, 2025 - $5.90
52-week High
Nov 06, 2024 - $28.83
Valuation
Market Cap
$729.04M - Small Cap
Enterprise Value
-$122.26M
Price/Sales (TTM)
1.94
Price/Book (Q)
1.19
Dividends and Shares
Shares Outstanding
73.00
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.arvinas.com
Phone Number
203 535 1456
Address
5 Science Park
New Haven, CT 06511
Country
United States
Year Founded
2013
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers... more
NASDAQ 10/31/2025 1:46PM Eastern Quotes delayed